

# Highly Potent Synthetic Polyamides, Bisdistamycins, and Lexitropsins as Inhibitors of Human Immunodeficiency Virus Type 1 Integrase

NOURI NEAMATI, ABHIJIT MAZUMDER, SANJAY SUNDER, JOSHUA M. OWEN, MANJU TANDON, J. WILLIAM LOWN, and YVES POMMIER

Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, Bethesda, Maryland 20892 (N.N., A.M., S.S., J.M.O., Y.P.), and Department of Chemistry, University of Alberta, Edmonton A8, T6G 2G2, Canada (M.T., J.W.L.)

Received February 10, 1998; Accepted April 17, 1998

This paper is available online at <http://www.molpharm.org>

## ABSTRACT

Alignment of the available human immunodeficiency virus type 1 (HIV-1) viral DNA termini [U5 and U3 long terminal repeats (LTRs)] shows a high degree of conservation and the presence of a stretch of five or six consecutive adenine and thymine (AT) sequences ~10 nucleotides away from each LTR end. A series of AT-selective minor-groove binders, including distamycin and bisdistamycins, bisnetropsins, novel lexitropsins, and the classic monomeric DNA binders Hoechst 33258, 4'-diamino-2-phenylindole, pentamidine, berenil, spermine, and spermidine, were tested for their inhibitory activities against HIV-1 integrase (IN). Although netropsin, distamycin, and all other monomeric DNA binders showed weak activities in the range of 50–200  $\mu\text{M}$ , some of the polyamides, bisdistamycins, and lexitropsins were remarkably active at nanomolar concentrations. Bisdistamycins

were 200 times less potent when the conserved AAAAT stretch present in the U5 LTR was replaced with GGGGG, consistent with the preferred binding of these drugs to AT sequences. DNase I footprinting of the U5 LTR further demonstrated the selectivity of these bisdistamycins for the conserved AT sequence. The tested compounds were more potent in  $\text{Mg}^{+2}$  than in  $\text{Mn}^{+2}$  and inhibited IN<sup>50–212</sup> deletion mutant in disintegration assays and the formation of IN/DNA complexes. The lexitropsins also were active against HIV-2 IN. Some of the synthetic polyamides exhibited significant antiviral activity. Taken together, these data suggest that selective targeting of the U5 and U3 ends of the HIV-1 LTRs can inhibit IN function. Polyamides might represent new leads for the development of antiviral agents against acquired immune deficiency syndrome.

The rapid emergence of HIV strains resistant to available drugs (Arts and Wainberg, 1996; De Clercq, 1996; Erickson and Burt, 1996) implies that effective treatment modalities will require the use of a combination of drugs targeting different sites of the HIV life cycle (Schinazi, 1991; Johnson, 1994; De Clercq, 1995; Larder *et al.*, 1995). As part of a program to develop novel antiviral agents, we sought to determine the role of specific DNA binding agents as possible inhibitors of HIV-1 IN. IN is an important target for intervention by chemotherapeutics, and to date several inhibitors of this enzyme have been reported (for recent reviews, see Neamati *et al.*, 1997c; Pommier *et al.*, 1997). IN is responsible for the insertion of the viral DNA into a host chromosome. This process is essential for effective viral replication and can be reproduced *in vitro* using recombinant IN and short oligonucleotides (Katz and Skalka, 1994; Rice *et al.*, 1996).

Integration takes place in two consecutive steps. Initially, IN processes the linear viral DNA by removing two nucleotides from each 3'-end, leaving the recessed 3'-OH termini. This reaction is followed by transesterification of phosphodiester bonds in which each processed viral 3' terminus becomes linked to a 5'-phosphate of host DNA strand. These two steps, known as 3'-processing and 3'-end joining (strand transfer), can be easily measured in an *in vitro* assay using purified recombinant HIV-1 IN and an oligonucleotide corresponding to the U5 region of HIV LTR sequence.

IN binds to the viral DNA sequences located at both extremities of the LTRs. Because these sequences are highly conserved in all HIV genomes (Fig. 1), they could provide potential targets for the selective inhibition of integration. In addition, both the U5 and U3 LTRs contain a conserved AT-rich sequence ~10 base pairs from the viral ends (Fig. 1). Netropsin and distamycin (Fig. 2) bind tightly to AT sequences of B-DNA with little affinity for single-stranded nucleic acids, double-stranded RNA, or DNA/RNA hybrids.

This work was supported by grants from the National Institutes of Health Intramural AIDS Targeted Antiviral Program (N.N., A.M., S.S., J.M.O., Y.P.) and the National Cancer Institute of Canada (M.T., J.W.L.).

**ABBREVIATIONS:** HIV-1, human immunodeficiency virus type-1; IN, integrase; LTR, long terminal repeat; ES, electrospray ionization; SDS, sodium dodecyl sulfate; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; TLC, thin layer chromatography, DMF, dimethylformamide; MES, 3-(*N*-morpholino)propanesulfonic acid.

These molecules have an intrinsic twist that favors insertion into the minor groove of B-DNA (Zimmer *et al.*, 1977, 1983; Kopka *et al.*, 1985; Kopka and Larsen, 1992).


In a search for selective DNA binders with modified properties, novel lexitropsins were designed and synthesized (Lown, 1988, 1994; Lown *et al.*, 1989). Recent studies demonstrated that polyamides can be synthesized to achieve highly selective recognition of the four Watson-Crick base pairs in the DNA minor groove (Helene, 1998; White *et al.*, 1998). In addition, polymethylene-linked lexitropsins were shown to exhibit antiviral activity (Lown *et al.*, 1989; Wang and Lown, 1992). However, their antiviral mechanism is not well understood.

The current report stems from our continuing efforts to identify novel IN inhibitors from compounds that exhibit

antiviral activity in cellular assays. Herein, we show that synthetic polyamides that interact selectively with the conserved AT stretch present in the HIV LTRs can inhibit integrations at submicromolar concentrations.

### Materials and Methods

**Chemistry.** All chemicals used were of reagent grade. The reactions were carried out in anhydrous tetrahydrofuran that was dried over sodium/benzophenone and distilled fresh at the time of reaction. Dimethylformamide and triethylamine were distilled and stored over molecular sieves (4 Å). The progress of the reaction was monitored by analytical TLC using silica gel (60F-254 mesh; Merck Research Labs, West Point, PA)-coated aluminum-backed plates. Preparative separations were performed by column chromatography on flash silica gel (70-230 mesh; Merck). Melting points were deter-



**Fig. 1.** Nucleotide sequence alignment of the LTR U3 and U5 regions of 43 HIV-1 strains. *Top*, HIV-1 provirus with the LTRs and the three genes *gag*, *pol*, and *env*. *Dashes*, identity. *Periods*, gaps in the nucleotide sequence. *Shaded region*, location of the conserved AT sequence. The sequences were obtained from the Los Alamos HIV Sequence Database Web site (<http://hiv-web.lanl.gov/>).

mined on an electrothermal melting point apparatus (Fisher-John) and are uncorrected.  $^1\text{H}$  NMR spectra were recorded on a Bruker AM-300 spectrometer, the samples were prepared in dimethylsulfoxide- $d_6$  unless otherwise specified, and the chemical shifts were reported in  $\delta$  ppm with respect to tetramethylsilane as an internal standard. New products were characterized by elemental analysis, mass spectroscopic analysis, or both using ES on a Micromass Zabspec Hybrid Sector TOF.

**Representative synthesis:**  $N,N'$ -di{1-methyl-2-[1-methyl-2-(1-methyl-2-carboxamido(3-dimethylaminopropyl)-4-pyrrole)-carboxamido-4-pyrrole]carboxamido-4-pyrrolyl}-phenyl-1,4-dicarboxamide (**26**). Nitrodistamycin **7a** (0.3 g, 0.6 mmol) was taken in DMF and methanol (10 ml, 1:1, v/v) and hydrogenated using Pd-C (10%, 150 mg) on a Parr shaker apparatus at 40 psi for 2 hr at 22°. The catalyst was removed by filtration and washed with methanol. The filtrate was evaporated, and the contents were dried under high vacuum to remove the traces of the solvent. The aminodistamycin **7b**, so obtained, was redissolved in anhydrous DMF (4 ml), the solution cooled down to 0°, and 1,4-phenyl diacid dichloride (61 mg, 0.3 mmol), predissolved in anhydrous tetrahydrofuran (4 ml), was added to it followed by 0.5 ml of triethylamine. The reaction mixture was stirred for 2 hr at 22°, at which time the TLC showed complete consumption of **7b**. The solvent was removed *in vacuo*, and the crude product was purified on a silica gel column using  $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$  (7:3:0.1, v/v/v) as eluent to collect pure **26** (160 mg, 50%); melting point  $>300^\circ$  [ $^1\text{H}$  NMR  $\delta$  1.60 [p,  $J = 7.0$  Hz, 4 H, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 2.16 [s, 12 H, 2  $\text{CH}_2\text{-N}(\text{CH}_3)_2$ ], 2.28 [t,  $J = 7.0$  Hz, 4 H, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.18 [dt,  $J = 6.0$  Hz,  $J = 7.0$  Hz, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.78, 3.86, and 3.90 (3 s, 18 H, each for 6 protons of pyrrolyl N- $\text{CH}_3$ ), 6.84, 7.04, 7.14, 7.20, 7.25, and 7.38 (6 d,  $J = 2.0$  Hz, 12 H, each for 2H of pyrrole ring), 8.08 (s, 4 H, phenyl protons), 8.09 (t,  $J = 6.0$  Hz, and two CONH- $\text{CH}_2$ , merged with phenylic protons), 9.9, 10.02, and 10.50 (3 s, 6 H, each s for two pyrrolyl NHCO); ES $^+$  calc. for  $\text{C}_{54}\text{H}_{66}\text{N}_{16}\text{O}_8$ , 1067.18; found 1067.50 ( $\text{M}^+$ , 100%)].


Other bisdistamycins were synthesized in a similar way, and the related data are described below.

$N,N'$ -Di{1-methyl-2-[1-methyl-2-(1-methyl-2-carboxamido(3-dimethylaminopropyl)-4-pyrrole)-carboxamido-4-pyrrolyl]-carboxamido-4-pyrrolyl}-phenyl-1,3-dicarboxamide (**27**). This product was isolated in same way as **26**. Yield 225 mg (70%); melting point  $295^\circ$  [ $^1\text{H}$  NMR  $\delta$  1.64 [p,  $J = 7.0$  Hz, 4 H, two

$\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 2.16 [s, 12 H, 2  $\text{N}(\text{CH}_3)_2$ ], 2.30 (t,  $J = 7.0$  Hz, 4 H, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.20 [dt,  $J = 6.0$  Hz,  $J = 7.0$  Hz, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.80, 3.88, and 3.94 (3 s, 18 H, each for 6 protons of pyrrolyl N- $\text{CH}_3$ ), 6.86, 7.06, 7.14, 7.20, 7.30, and 7.40 (6 d,  $J = 2.0$  Hz, 12 H, each for 2 H of pyrrole ring), 7.70 (t,  $J = 7.5$  Hz, 1 H, phenylic H-5), 8.10 (m, 4 H, phenylic H-4 and H-5 merged with 2 CONH- $\text{CH}_2$  protons), 8.50 (s, 1 H, phenyl H-2), 9.90, 10.02, and 10.54 (3 s, 6 H, each s for 2 pyrrolyl NHCO); ES $^+$  calc. for  $\text{C}_{54}\text{H}_{66}\text{N}_{16}\text{O}_8$ , 1067.18; found 1067.60 ( $\text{M}^+$ , 100%)].

**2N-[1-Methyl-2-[1-methyl-2-(1-methyl-2-carboxamido(3-dimethylaminopropyl)-4-pyrrole)-carboxamido-4-pyrrolyl]-2-carboxy benzamide (28)**. The reaction of **7b** (285 mg, 0.6 mmol) with 1,2-phenyl diacid chloride (50 mg, 0.3 mmol) in the presence of triethylamine (0.1 ml) using DMF as a solvent afforded this product at a higher than anticipated  $R_f$  value. Raising the temperature of the reaction mixture to  $65^\circ$  did not result in any change in the nature of the reaction, and some unconsumed **7b** always existed in the reaction mixture (detected on TLC plate). The solvent was removed *in vacuo*, and the crude product was purified on a silica gel column using  $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$  (7:3:0.1, v/v/v) as eluent to afford 100 mg (54%) of pure **28**. melting point  $173^\circ$  [ $^1\text{H}$  NMR  $\delta$  1.80 [p,  $J = 7.0$  Hz, 4 H, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 2.48 [s, 6 H,  $\text{N}(\text{CH}_3)_2$ ], 2.68 [t,  $J = 7.0$  Hz, 2 H,  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.24 [dt,  $J = 6.0$  Hz,  $J = 7.0$  Hz, 2 H,  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.80, 3.85, and 3.90 (3 s, 9H, each for 3 pyrrolyl N $\text{CH}_3$ ), 6.86, 6.98, 7.05, 7.20, 7.26, and 7.30 (6 d,  $J = 2.0$  Hz, 6H, each for 2 H of pyrrole ring), 7.50 (m, 2 H, phenylic H-4 and H-5), 7.65 (dd,  $J = 7.0$  Hz,  $J = 2.0$  Hz, 1 H, phenylic H-6), 7.75 (dd,  $J = 7.0$  Hz,  $J = 2.0$  Hz, 1 H, phenylic H-3), 8.15 (t,  $J = 6.0$  Hz, CONH- $\text{CH}_2$ ), 9.90, and 10.00 (2 s, 2 H, each s for 2 pyrrolyl NHCO); 11.50 (broad s, 1 H, COOH); ES $^+$  calc. for  $\text{C}_{31}\text{H}_{36}\text{N}_8\text{O}_6$  616.65, found 617.20 ( $\text{M}^+$  100%)].

**N-[1-Methyl-2-[1-methyl-2-(1-methyl-2-carboxamido(3-dimethylaminopropyl)-4-pyrrole)-carboxamido-4-pyrrolyl]-carboxamido-4-pyrrolyl]-phthalimide (29)**. Phthalic acid (50 mg, 0.3 mmol) and 1,1'-carbonyldiimidazole (100 mg, 0.6 mmol) were heated at  $80^\circ$  in anhydrous DMF and  $\text{CH}_3\text{CN}$  (3:1, 3.0 ml, v/v/v) for 2 hr and cooled to 0°. Distamycin **7b** (285 mg, 0.6 mmol), predissolved in anhydrous DMF (2.0 ml), was added to this reaction mixture, and the contents were stirred for 2 hr at 22°. A TLC examination at this time showed complete disappearance of aminodistamycin and formation of a new product. The solvent was evaporated *in vacuo*, and the crude product was purified on a silica gel column



**Fig. 2.** Structures of minor-groove binders netropsin, distamycin, Hoechst 33258, 4'-diamino-2-phenylindole, pentamidine, and berenil.

using  $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$  (7:3:0.05) as eluent to give pure **29**. Yield 80 mg (44%); melting point  $220^\circ$  [ $^1\text{H NMR}$   $\delta$  1.60 [p,  $J = 7.0$  Hz, 2 H,  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 2.10 [s, 6 H,  $\text{N}(\text{CH}_3)_2$ ], 2.25 (t,  $J = 7.0$  Hz, 2 H,  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.20 [dt,  $J = 6.0$  Hz,  $J = 7.0$  Hz, 2 H,  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.80, 3.88, and 3.98 (3 s, 9 H, each for 3 pyrrolyl  $\text{NCH}_3$ ), 6.82, 7.08, 7.20, 7.30, 7.34, and 7.38 (6 d,  $J = 2.0$  Hz, 6 H, each for one pyrrolyl CH), 7.88–7.95 (m, 4 H, aromatic), 8.10 (t,  $J = 6.0$  Hz,  $\text{CONH-CH}_2$ ), 9.90 and 10.10 (2 s, 2 H, each s for 2 pyrrolyl  $\text{NHCO}$ );  $\text{ES}^+$  calc. for  $\text{C}_{31}\text{H}_{34}\text{N}_8\text{O}_5$  598.63, found 599.10 ( $\text{M}^+$  100%).

***N,N'*-Di{[1-methyl-2-[1-methyl-2-(1-methyl-2-carboxamido(3-dimethylaminopropyl)-4-pyrrole)-carboxamido-4-pyrrole]-carboxamido-4-pyrrolyl]-pyridine-2,5-dicarboxamide (30)}**. Reaction of 2,5-pyridine dicarboxy dichloride (61 mg, 0.3 mmol) with amino distamycin **7b** (285 mg, 0.6 mmol) in the presence of triethylamine (0.5 ml), using anhydrous DMF as a solvent, gave the crude product. This material was purified the same way as described for **26**. Yield 270 mg (85%); melting point  $>300^\circ$  [ $^1\text{H NMR}$   $\delta$  1.60 [p,  $J = 7.0$  Hz, 4 H, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 2.14 [s, 12 H, 2  $\text{N}(\text{CH}_3)_2$ ], 2.25 [t,  $J = 7.0$  Hz, 4 H, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.20 [dt,  $J = 6.0$  Hz,  $J = 7.0$  Hz, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.78 and 3.85 (2 s, 12 H, each for 6 protons of pyrrolyl  $\text{N-CH}_3$ ), 3.90 and 3.92 (2 s, 6 H, each for 3 protons of pyrrolyl  $\text{N-CH}_3$ ), 6.84, 7.05, 7.12, 7.19, 7.26, 7.90, and 7.95 (7 d,  $J = 2.0$  Hz, total 10 H of pyrrole ring) 8.10 (t,  $J = 6.0$  Hz, 2 H of 2  $\text{CONH-CH}_2$ ), 8.25 (d,  $J = 7.0$  Hz, 1 H, pyridyl H-3), 8.50 (dd,  $J = 7.0$  Hz,  $J = 2.0$  Hz, 1 H, pyridyl H-4), 9.20 (d,  $J = 2.0$  Hz, 1 H, pyridyl H-6), 9.90 and 10.00 (2 s, 4 H, each for 2  $\text{NHCO}$ ), 10.75 and 10.90 (2 s, 2 H, each for 1 H of  $\text{NHCO}$ );  $\text{ES}^+$  calc. for  $\text{C}_{53}\text{H}_{65}\text{N}_{17}\text{O}_8$  1068.17, found 1068.50 ( $\text{M}^+$  100%).

***N,N'*-Di{[1-methyl-2-[1-methyl-2-(1-methyl-2-carboxamido(3-dimethylaminopropyl)-4-pyrrole)-carboxamido-4-pyrrole]-carboxamido-4-pyrrolyl]-pyridine-2,4-dicarboxamide (31)}**. This product was obtained following the synthetic procedure as described for **26**. The chromatographic purification, using  $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$  (7:3:0.05, v/v) as eluent afforded 240 mg (75%) of pure **31** as yellow solid; melting point  $200^\circ$  [ $^1\text{H NMR}$   $\delta$  1.60 [p,  $J = 7.0$  Hz, 4 H, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 2.18 [s, 12 H, 2  $\text{N}(\text{CH}_3)_2$ ], 2.26 [t,  $J = 7.0$  Hz, 4 H, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.20 [dt,  $J = 6.0$  Hz,  $J = 7.0$  Hz, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.80, 3.86, 3.89, and 3.91 (4 s, 24 H, each for 6 protons of pyrrolyl  $\text{N-CH}_3$ ), 6.84, 7.06, 7.16, 7.18, 7.26, 7.42, and 7.44 (7 d,  $J = 2.0$  Hz, total 12 H of 6 pyrrole rings) 8.10 (m, 3 H; 2 H of 2  $\text{CONH-CH}_2$  and 1 H of pyridyl H-5), 8.62 (d,  $J = 1.5$  Hz, 1 H, pyridyl H-3), 8.90 (d,  $J = 5.5$  Hz, 1 H, pyridyl H-6), 9.90 and 10.02, 10.88, and 10.91 (4 s, 4 H, 1 H for each  $\text{NHCO}$ );  $\text{ES}^+$  calc. for  $\text{C}_{53}\text{H}_{65}\text{N}_{17}\text{O}_8$  1068.17, found 1068.30 ( $\text{M}^+$  100%).

***N,N'*-Di{[1-methyl-2-[1-methyl-2-(1-methyl-2-carboxamido(3-dimethylaminopropyl)-4-pyrrole)-carboxamido-4-pyrrole]-carboxamido-4-pyrrolyl]-pyridine-2,6-dicarboxamide (32)}**. The crude mixture was purified on a silica gel column using  $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$  (7:3:0.05, v/v) to obtain 260 mg (81%); melting point  $228\text{--}30^\circ$  [ $^1\text{H NMR}$   $\delta$  1.65 [p,  $J = 7.0$  Hz, 4 H, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 2.25 [s, 12 H, 2  $\text{N}(\text{CH}_3)_2$ ], 2.40 (t,  $J = 7.0$  Hz, 4 H, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.20 [dt,  $J = 6.0$  Hz,  $J = 7.0$  Hz, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.80, 3.88 and 3.96 [3 s, 18H, each for 6 protons of pyrrolyl  $\text{N-CH}_3$ ], 6.86, 7.10, 7.18, 7.25, 7.30 and 7.45 (6 d,  $J = 2.0$  Hz, 12 H, each for 2 H of pyrrole ring), 8.08 (t,  $J = 6.0$  Hz, 2  $\text{CONH-CH}_2$ ), 8.30 (dd,  $J = 6.5$  Hz, 1 H, pyridyl H-4), 8.35 (dd,  $J = 6.5$  Hz,  $J = 2.0$  Hz, 2 H, pyridyl H-3 and H-5), 9.90, 10.10 and 11.10 (3 s, 6H, each s for 2 pyrrolyl  $\text{NHCO}$ );  $\text{ES}^+$  calc. for  $\text{C}_{53}\text{H}_{65}\text{N}_{17}\text{O}_8$ , 1068.17; found 1068.50 ( $\text{M}^+$ , 100%).

***N,N'*-Di{[1-methyl-2-[1-methyl-2-(1-methyl-2-carboxamido(3-dimethylaminopropyl)-4-pyrrole)-carboxamido-4-pyrrole]-carboxamido-4-pyrrolyl]-pyridine-3,5-dicarboxamide (33)}**. Yield 241 mg (76%); melting point  $210^\circ$  [ $^1\text{H NMR}$   $\delta$  1.60 [p,  $J = 7.0$  Hz, 4 H, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 2.20 [s, 12 H, 2  $\text{N}(\text{CH}_3)_2$ ], 2.25 [t,  $J = 7.0$  Hz, 4 H, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.20 [dt,  $J = 6.0$  Hz,  $J = 7.0$  Hz, 2  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.78, 3.84, and 3.90 (3 s, 18H, each for 6 protons of pyrrolyl  $\text{N-CH}_3$ ), 6.84, 7.06, 7.15 7.20, 7.28, and 7.40

(6 d,  $J = 2.0$  Hz, 12 H, each for 2 H of pyrrole ring), 8.10 (t,  $J = 6.0$  Hz, 2  $\text{CONH-CH}_2$ ), 8.80 (t,  $J = 2.0$  Hz, 1 H, pyridyl H-4), 9.26 (d,  $J = 2.0$  Hz, 2 H, pyridyl H-2 and H-6), 9.90, 10.05, and 10.78 (3 s, 6 H, each s for 2 pyrrolyl  $\text{NHCO}$ );  $\text{ES}^+$  calc. for  $\text{C}_{53}\text{H}_{65}\text{N}_{17}\text{O}_8$ , 1068.17; found 1068.60 ( $\text{M}^+$ , 100%).

***N*-{[1-Methyl-2-[1-methyl-2-(1-methyl-2-carboxamido(3-dimethylaminopropyl)-4-pyrrole)-carboxamido-4-pyrrole]-carboxamido-4-pyrrolyl]-4-carboxy pyridine-3-carboxamide (34)}**. This product was obtained following the procedure described for **28**. Yield 95 mg (51%); melting point  $192^\circ$ ; [ $^1\text{H NMR}$   $\delta$  1.78 [p,  $J = 7.0$  Hz, 2 H,  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 2.48 [s, 6 H,  $\text{N}(\text{CH}_3)_2$ ], 2.78 [t,  $J = 7.0$  Hz, 2 H,  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.24 [dt,  $J = 6.0$  Hz,  $J = 7.0$  Hz, 2 H,  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.80, 3.85 and 3.90 (3 s, 9 H, each for 3 pyrrolyl  $\text{NCH}_3$ ), 6.90, 7.04, 7.06, 7.20, 7.30, and 7.40 (6 d,  $J = 2.0$  Hz, 6 H, each for 1 pyrrolyl CH), 7.46 (d,  $J = 5.0$  Hz, 1 H, pyridyl H-5), 8.12 (t,  $J = 6.0$  Hz,  $\text{CONH-CH}_2$ ), 8.56 (d,  $J = 5.0$  Hz, 1 H, pyridyl H-6), 9.0 (s, 1 H, pyridyl H-2), 9.94 and 10.00 (2 s, 2 H, each for 1 H of  $\text{NHCO}$ ), 13.50 (broad s, 1 H,  $\text{COOH}$ );  $\text{ES}^+$  calc. for  $\text{C}_{30}\text{H}_{35}\text{N}_9\text{O}_6$  618.64, found 618.64 ( $\text{M}^+$  100%).











***N*-{[1-Methyl-2-[1-methyl-2-(1-methyl-2-carboxamido(3-dimethylaminopropyl)-4-pyrrole)-carboxamido-4-pyrrole]-carboxamido-4-pyrrolyl]-3-carboxy pyridine-2-carboxamide (35)}**. This product was obtained following the synthetic procedure as described for **28**. Yield 100 mg (54%); melting point  $187^\circ$  [ $^1\text{H NMR}$   $\delta$  1.70 [p,  $J = 7.0$  Hz, 2 H,  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 2.30 [s, 6 H,  $\text{N}(\text{CH}_3)_2$ ], 2.50 (t,  $J = 7.0$  Hz, 2 H,  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.22 [dt,  $J = 6.0$  Hz,  $J = 7.0$  Hz, 2 H,  $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-N}(\text{CH}_3)_2$ ], 3.80, 3.85, and 3.90 (3 s, 9 H, each for 3 pyrrolyl  $\text{NCH}_3$ ), 6.85, 7.06, 7.08, 7.18, 7.25, and 7.32 (6 d,  $J = 2.0$  Hz, 6 H, each for 1 pyrrolyl CH), 7.50 (dd,  $J = 5.0$  Hz,  $J = 7.5$  Hz, 1 H, pyridyl H-5), 8.02 (dd,  $J = 1.5$  Hz,  $J = 7.5$  Hz, 1 H, pyridyl H-4), 8.10 (t,  $J = 6.0$  Hz, 1 H,  $\text{CONH-CH}_2$ ), 8.62 (dd,  $J = 5.0$  Hz,  $J = 1.5$  Hz, 1 H, pyridyl H-6), 9.90 and 10.00 (2 s, 2 H, each for 1 H of  $\text{NHCO}$ ), 10.98 (broad s, 1 H,  $\text{COOH}$ );  $\text{ES}^+$  calc. for  $\text{C}_{30}\text{H}_{35}\text{N}_9\text{O}_6$  618.64, found 618.10 ( $\text{M}^+$  100%).

**Preparation of radiolabeled DNA substrates, IN proteins and assays, electrophoresis and quantification, and anti-HIV assays in cultured cell lines.** These methods were performed essentially as described previously (Neamati *et al.*, 1997b). The  $\text{Mg}^{+2}$ -based assays were carried in the presence of 5% polyethylene glycol as described previously (Engelman and Craigie, 1995). The anti-HIV drug testing were performed at National Cancer Institute essentially as described by Weislow *et al.* (1989).

**Schiff base formation and chemical trapping.** IN was incubated with an oligonucleotide-containing an abasic site (see Fig. 7A) in reaction buffer as described above (Mazumder *et al.*, 1996a) for 2 min at room temperature. A freshly prepared solution of sodium borohydride (0.1 M final concentration) was added, and reaction was continued for an additional 5 min. An equal volume (16  $\mu\text{l}$ ) of  $2\times$  SDS-polyacrylamide gel electrophoresis buffer (100 mM Tris, pH 6.8, 4% 2-mercaptoethanol, 4% SDS, 0.2% bromphenol blue, 20% glycerol) was added to each reaction, and the reaction was heated at  $95^\circ$  for 3 min before loading a 20- $\mu\text{l}$  aliquot on a 12% SDS-polyacrylamide gel. The gel was run at 120 V for 1.5 hr, dried, and exposed in a PhosphorImager cassette. For inhibition of DNA binding experiments, IN (200 nM) was preincubated with the inhibitor (at the indicated concentration) for 30 min at  $30^\circ$  before the subsequent addition of the radiolabeled viral DNA substrate (20 nM) and borohydride. Gels were analyzed using a Molecular Dynamics PhosphorImager (Sunnyvale, CA).

**Footprinting experiments.** DNase I footprinting was performed in buffer containing 50 mM NaCl, 1 mM HEPES, pH 7.5, 50  $\mu\text{M}$  EDTA, 50  $\mu\text{M}$  dithiothreitol, 10% glycerol (w/v), 7.5 mM  $\text{MgCl}_2$ , 0.1 mg/ml bovine serum albumin, 10 mM 2-mercaptoethanol, 25 mM MES, pH 7.2, and 10 nM oligonucleotide. Lexitropsins were added to the reaction mixture and incubated at room temperature for 5 min. Digestion was achieved by the addition of DNase I (3 units/ml) for 1 min. The reaction was quenched with EDTA and  $2\times$  SDS-polyacrylamide gel electrophoresis buffer (100 mM Tris, pH 6.8, 4% 2-mercap-

TABLE 1  
Inhibition of HIV-1 IN catalytic activities and inhibition of HIV-1 replication in CEM cells by a series of polyamides


Compound No.	Structure	IC <sub>50</sub>		Cellular anti-HIV-1 data		
		3'-Processing	Integration	IC <sub>50</sub>	EC <sub>50</sub>	TI
1	Net-CO-Net	42.8; 78.4 <sup>a</sup>	29.0; 45.0	83.5	11.9	7.01
2	Net-CO(CH <sub>2</sub> ) <sub>2</sub> CO-Net	5.8 ± 1.6	7.5 ± 2.5	75.3	12	6.3
3	Net-CO(CH <sub>2</sub> ) <sub>6</sub> CO-Net	37.6; 64.8	40.3; 10.0	57	3.9	14.6
4	Net-CO(CH <sub>2</sub> ) <sub>10</sub> CO-Net	16.4; 33.8	29.2; 10.0	78	6.6	11.7
5		98.9	30.0	148	5.3	28
6		7.5 ± 1.3	6.9 ± 1.4	284	3.55	80
7	Distamycin	56.9	50.2	30.4	NR <sup>c</sup>	
8		0.1 ± 0.08	0.09 ± 0.01	4.7	0.39	12
9		43.7 ± 4.6	10.0			
10		72 ± 64	10.0	140	21	6.6
11		0.08 ± 0.05	0.1 ± 0.03	69	1.6	43
12		33.5	0.4	69	9.8	7.0
13		0.8	0.3	207	10.4	19.8
14		30.7 ± 8.1	10.0	71	16	4.5
15		36.5 ± 4.9	10.0			
16	Dist-CO(CH <sub>2</sub> ) <sub>2</sub> CO-Dist	21 ± 8.5	9.5 ± 1.2	41	41	1.0
17	Dist-CO(CH <sub>2</sub> ) <sub>6</sub> CO-Dist	0.025; 0.09 (4.9) <sup>b</sup>	0.005; 0.009 (2.2)			
18	Dist-CO(CH <sub>2</sub> ) <sub>8</sub> CO-Dist	0.032; 0.09 (7.4)	0.015; 0.09 (6.5)	29	14	2.0
19	Dist-CO(CH <sub>2</sub> ) <sub>22</sub> CO-Dist	12.2 ± 3.3	8.0			
20	Hoechst 33258	>100	>100			
21	DAPI	>100	>100			
22	Pentamidine	>100	>100			
23	Berenil	>100	>100			
24	Spermine	>100	>100			
25	Spermidine	>100	>100			











<sup>a</sup> Second independent experiment.

<sup>b</sup> Numbers in parantheses refer to GC rich DNA duplex.

<sup>c</sup> NR, not reached.

TABLE 2  
Inhibition of HIV-1 and HIV-2 IN catalytic activities and inhibition of HIV-1 replication in CEM cells by a series of novel lexitropsins



Compound No.	Structure	HIV-1 IC <sub>50</sub>			HIV-2 IC <sub>50</sub>		Cellular anti-HIV-1 data	
		3'-Processing	Integration	Disintegration	3'-Processing	Integration	IC <sub>50</sub>	EC <sub>50</sub>
26		0.19 ± 0.1	0.07 ± 0.02	0.61	$\mu\text{M}$ 0.27 0.28	0.07 0.07	>100	>100
27		>100	>100	77	66.9	66.9	>100	>100
28		>100	>100	>100	>100	>100	>200	>200
29		33.3 11.1	33.3 11.1	28.5 10.2	ND	ND	56 ± 10	52 ± 4
30		0.31 ± 0.2	0.28 ± 0.2	0.68 0.18	0.37 0.52	0.37 0.05	>100 >100	0.3 NR
31		11.1 33.3	11.1 33.3	3.7	ND	ND	>100	>100
32		33.3 100	33.3 100	57 14.1	>100	>100	>100	>100
33		100	100	86	>100	>100	>100	>100
34		>100	>100	>100	>100	>100	ND	ND
35		>100	>100	>100	>100	>100	ND	ND

Values with the standard deviations are from three independent experiments; the others are from two independent experiments. NR, not reached due to cytotoxicity.

toethanol, 4% SDS, 0.2% bromphenol blue, 20% glycerol), and an aliquot (5  $\mu$ l) was electrophoresed on a denaturing 20% polyacrylamide gel as described above.

## Results


### Synthesis of Dimethylaminopropylamido Analogs of Distamycin (Novel Lexitropsins)

**Preparation of aryl acid chlorides.** Except for commercially available diacid chlorides, these linkers were prepared fresh, before their coupling with distamycin, from diacids. The acids were taken in thionyl chloride (5–10 mol in excess) with 2 or 3 drops of anhydrous dimethylformamide, and the mixture was heated at 65° for 2–3 hr. Excess of thionyl chloride was removed *in vacuo*, the contents were coevaporated with anhydrous methylene chloride, and the diacid chloride formed was used as such in its coupling with aminodistamycin.


**3-[1-Methyl-4-[1-methyl-4-(1-methyl-4-nitropyrrole-2-carboxamido)pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]dimethylaminopropane (distamycin, 7a).** Distamycin (7a) was synthesized according to a reported procedure (Nishiwaki *et al.*, 1988). Distamycin (7a) was the key intermediate for the synthesis (Figs. 3 and 4) of new rigidly linked bislexitropsins (26–35).

### Targeting HIV-1 LTR as an Alternative Strategy to Inhibit IN Function

The viral DNA sequences that are required and sufficient for recognition by IN are the distal ends of the LTRs. To determine how conserved are the HIV-1 LTRs among all the reported HIV-1 strains, we aligned the sequences from the Los Alamos HIV sequence Database (<http://hiv-web.lanl.gov/>). The termini of the HIV-1 LTRs seemed highly conserved among 43 available HIV-1 strains (Fig. 1). It is noticeable that a conserved AT stretch was identified ~10 bases away from both ends of the U3 and U5 LTRs. Thus, we envisaged that lexitropsins, or information-reading mole-



**Fig. 3.** Catalytic reduction of nitrolexitropsin 7a to aminolexitropsin reagent 7b.




**Fig. 4.** General synthetic scheme to linked bislexitropsins.

cules, with a predictable base and sequence recognition capability could target these sites and block integration.

### Inhibition of IN Catalytic Activities by a Series of Polyamides

**Netropsin and distamycin analogs.** Thirty-five polyamides were tested for anti HIV-1 IN activity (Tables 1 and 2) using a dual assay measuring both 3'-processing and 3'-end joining (strand transfer or integration) (Fig. 5). The bisnetropsin (1–6) and bisdistamycin (8–19) derivatives composed of two netropsin or distamycin molecules separated by aliphatic or aromatic linkers with different size and geometry were examined (Table 1). The result presented in Table 1 attests to the remarkable relationship between the structure of various derivatives and their IC<sub>50</sub> values against IN. For example, the striking difference in potency shown by distamycin 7 compared with the potency of bisdistamycin derivatives suggests the importance of the dimeric structure. The linkers separating the two distamycin moieties contribute to potency, and the geometry of the linker seems critical for



**Fig. 5.** HIV-1 IN catalytic assays. A, A 21-mer blunt-end oligonucleotide corresponding to the U5 end of the HIV-1 proviral DNA, 5'-end-labeled with <sup>32</sup>P, is reacted with purified HIV-1 IN. The initial step involves nucleolytic cleavage of two bases from the 3'-end, resulting in a 19-mer oligonucleotide. The second step, 3'-end joining or strand transfer, involves joining of this recessed 3'-end to the 5'-end of an IN-induced break in another identical oligonucleotide, which serves as the target DNA. B, Concentration-dependent inhibition of HIV-1 IN by compounds 8, 11, 13, and 12. Lane 1, DNA alone. Lanes 2, 13, and 24, DNA plus IN. Lanes 3–23, DNA and IN in the presence of indicated concentrations ( $\mu$ M) of drugs.

effective inhibition. The 1,4-disubstituted *para* derivative **8** exhibited markedly higher potency than the 1,2-*ortho* and 1,3-disubstituted *meta* derivative **9** and **10**, respectively. A similar observation was made when the pyridinyl derivative with *para* substitution (compound **11**) was compared with the *meta* substituted derivative **12**. In addition, the linear 1,2-*trans* substituted compound **13** was 30–50 times more potent than the more rigid cyclobutanyl and norbornyl derivatives **14** and **15**, respectively. Compound **12** exhibited remarkable selectivity for the 3'-end joining (strand transfer) step (Fig. 5B). Moreover, the length of the linker also contributes to potency. The dimers with the short dimethylene linker (derivative **16**) or a long aliphatic chain linker (derivative **19**) exhibited a significantly reduced potency compared with compound **17** or **18** with hexamethylene or octamethylene linkers, respectively.

**Novel lexitropsins.** A series of novel polyamides also was examined (Table 2). As in the case of the bisdistamycins presented in Table 1, a common structural feature required for potency seems to be the *para* substitution. For example, the 1,4-disubstituted derivative **26** was markedly more potent than its corresponding 1,3-disubstituted analog, **27**. In addition, the 1,4-disubstituted pyridinyl derivative **30** was more potent than its corresponding 1,3-disubstituted derivatives **31**, **32**, and **33**. In accord with the results for the monosubstituted minor-groove binders presented in Table 1, the monosubstituted lexitropsins **28**, **34**, and **35** were practically inactive. We also found that the novel lexitropsins were active against HIV-2 IN (Table 2).

**Classic minor-groove binders.** Netropsin and distamycin (Fig. 2) are natural oligopeptide antibiotics with antitumor, antiviral, and antibacterial activities (Zimmer *et al.*, 1977, 1983; Kopka *et al.*, 1985; Kopka and Larsen, 1992). Both antibiotics are known to bind to AT-rich regions in the minor groove of B-DNA in nonintercalative fashion (Zimmer *et al.*, 1977, 1983; Kopka *et al.*, 1985; Kopka and Larsen, 1992). Netropsin, distamycin, Hoechst 33258, 4'-diamino-2-phenylindole, pentamidine, and berenil (Fig. 2), which possess a crescent shape, bind noncovalently in the DNA minor groove without insertion between the base pairs (Zimmer *et al.*, 1977, 1983; Kopka *et al.*, 1985; Kopka and Larsen, 1992). None of these monomeric groove binders (compounds **20–25**) exhibited significant activity at 100  $\mu\text{M}$  against IN (Table 1). Distamycin **7** was only weakly active with an  $\text{IC}_{50}$  value of  $\sim 50 \mu\text{M}$ . Thus, the ability of the polyamides examined to inhibit IN varied considerably. The difference in activity exceeded 2–3 orders of magnitude.

## Probing the Mechanism of IN Inhibition


### Effect of the polyamides on the HIV-1 IN core region.

To examine the mechanism of inhibition of IN, we used an IN deletion mutant,  $\text{IN}^{50-212}$ , which lacks the amino-terminal zinc-binding region and the carboxyl-terminal DNA-binding domain (Chow *et al.*, 1992; Bushman *et al.*, 1993). This mutant can catalyze an apparent reversal of the integration reaction known as disintegration (Chow *et al.*, 1992) (Fig. 6A). In the disintegration assay, the lexitropsin **26** was markedly more potent than lexitropsin **34** (Fig. 6B). The bisdistamycins **16**, **17**, **18**, and **19** exhibited  $\text{IC}_{50}$  values of 2.3, 0.009, 0.03, and 3.7  $\mu\text{M}$  (data not shown). The activity of the novel lexitropsins **27–36** in the disintegration assay with  $\text{IN}^{50-212}$  are indicated in Table 2. These results demonstrate that polyamides can interfere with the activity of the IN core region and that their inhibitory activity does not require the presence of the zinc-binding and carboxyl-terminal domains of IN.

**Global nucleophilic inhibition.** The 3'-processing reaction involves hydrolysis of a single phosphodiester bond 3' of the conserved CA-3' dinucleotide (Fig. 7A). However, in addition to this hydrolysis reaction, retroviral INs can use glycerol or the hydroxyl group of the viral DNA terminus as the nucleophile in the 3'-processing reaction, yielding a glycerol esterified to the 5'-phosphate, a circular dinucleotide or trinucleotide, respectively (Engelman *et al.*, 1991; Vink *et al.*, 1991; Mazumder *et al.*, 1996b) (Fig. 7A). To examine the effect of synthetic polyamides on the choice of nucleophiles in the 3'-processing reaction, a substrate DNA labeled at the 3'-end with  $^{32}\text{P}$ -cordycepin was used (Mazumder *et al.*, 1996b). Compounds **8**, **11**, **13**, and **12** inhibited glycerolysis, hydrolysis, and circular nucleotide formation similarly (Fig. 7B). This result indicates that lexitropsins block indiscriminately all the IN nucleophilic reactions.

**Divalent ion effects.** Although *in vitro* assays are generally more efficient with  $\text{Mn}^{+2}$  as a cofactor, it has been proposed that the physiological cation is  $\text{Mg}^{+2}$ . We compared the extent of 3'-processing and strand transfer for two representative derivatives, **8** and **11**, in the presence of  $\text{Mg}^{+2}$  and  $\text{Mn}^{+2}$ . Both compounds were more potent with  $\text{Mg}^{+2}$  than with  $\text{Mn}^{+2}$  (Fig. 8). This suggests that in contrast to polyhydroxylated aromatics (Fesen *et al.*, 1994; Hazuda *et al.*, 1997b; Neamati *et al.*, 1997a), polyamides do not interact selectively with the divalent metal of the IN catalytic site.

**Inhibition of DNA IN binding by polyamides.** A recently described DNA IN cross-linking assay (Mazumder *et*



**Fig. 6.** HIV-1 IN disintegration assay using the core truncated mutant  $\text{IN}^{50-212}$ . **A**, The substrate oligonucleotide mimics a strand transfer step product (i.e., a Y oligonucleotide containing a 15-mer oligonucleotide 5'-end-labeled with  $^{32}\text{P}$ ). HIV-1 IN-mediated disintegration generates a 30-mer oligonucleotide. **B**, Concentration-dependent inhibition of HIV-1 IN-mediated disintegration by compounds **26** and **34**.




*al.*, 1996a) was used. Briefly, a 21-mer oligonucleotide in which uracil was substituted for adenine in the conserved CA dinucleotide on the distal end of the U5 LTR was treated with uracil DNA glycosylase to generate an abasic site (Fig. 9A, *U*). Subsequent incubation with IN and stabilization with sodium borohydride of the Schiff base formed between free aldehyde on the DNA backbone and the amino group of lysines in the IN produced a cross-linked product running as a 39-kDa band after electrophoresis (Fig. 9B, *lane 2*). Compound **26** effectively inhibited the formation of IN/DNA complexes, and the lexitropsin **27** was considerably less potent (Fig. 9C). These results are in accord with the inhibition of DNA integration by these compounds (Table 2) and suggest that lexitropsins inhibit IN activity by blocking IN binding to its DNA substrate.


**DNA sequence selectivity of polyamides.** Because minor-groove binders such as distamycin and netropsins preferentially bind to AT sequences, we mutated the U5 DNA

substrate to replace the conserved AT sequence with GC (Fig. 10A). This replacement decreased the efficiency of 3'-processing by ~30%, whereas 3'-end joining became almost undetectable. The two most potent bisdistamycins, **17** and **18**, were compared for their ability to inhibit 3'-processing using the two DNA substrates. For both polyamides, inhibitory activity was ~200-fold less with the GC-containing oligonucleotide than with the physiological 21-mer oligonucleotide containing the conserved AT stretch (Fig. 10B). These results are consistent with the importance of DNA binding for IN inhibition by polyamides.

**DNase I footprinting.** A DNase I footprinting experiment using a labeled 21-mer was performed to examine further the binding of the highly potent bisdistamycins **17** and **18** to the U5 LTR (Fig. 11). Protection of the AT-rich domain was observed with both compounds, and this protection tended to extend toward the U5 end at higher concentrations with **17**. No such protection was observed using the GC oligonucleotide (see Fig. 10A and data not shown), which is consistent with the selective binding of lexitropsins to AT stretches.



**Fig. 7.** Differential use of nucleophiles in the site-specific cleavage of 3'-end-labeled substrate (3'-processing) by HIV-1 IN. A, Schematic representation of nucleophilic substitution of water, glycerol, or the 3'-hydroxyl group of the viral DNA terminus yielding a linear trinucleotide with a 5'-phosphate (*L*), a linear trinucleotide with a glycerol esterified to the 5'-phosphate (*G*), and a cyclic trinucleotide (*C*). \*, <sup>32</sup>P-labeled cordycepin. B, Global inhibition of nucleophilic attack in the 3'-processing reaction by compounds **8** (□), **11** (●), **13** (▼), and **12** (△).




**Fig. 8.** Concentration-dependent inhibition of HIV-1 IN by compounds **8** (□, ■) and **11** (○, ●) in the presence of Mn<sup>2+</sup> (○, □) or Mg<sup>2+</sup> (■, ●).

## Discussion

Earlier work showed that DNA intercalators can effectively inhibit HIV-1 integration (Carteau *et al.*, 1993; Fesen *et al.*, 1993; for review, see Neamati *et al.*, 1997c). However, intercalators have limited sequence specificity because they primarily interact with two adjacent base pairs. Thus, they would be expected to bind to numerous DNA sites, to affect cellular metabolism relatively indiscriminately, and to be too toxic for anti-acquired immune deficiency syndrome therapy. In the current study, we examined the activity of synthetic polyamides that can recognize with high selectivity DNA sequences from the DNA minor groove and exhibit antiviral activity.

Selective minor-groove binding to the conserved AT sequences in the LTRs seems to be the primary mechanism of inhibition of IN by the polyamides studied. First, the polyamides inhibited the binding of IN to its DNA substrate in the Schiff base assay at concentrations that effectively inhib-




**Fig. 9.** Inhibition of DNA binding of HIV-1 IN by lexitropsins **26** and **27**. A, Depurinated (*U*) duplex U5 oligonucleotide substrate. B, Phosphorimager picture showing the inhibition of 39-kDa DNA-IN cross-linked product in the presence of indicated concentrations of lexitropsins **26** and **27**. C, Quantification of the gel in B.

ited integration. Second, DNase I footprinting demonstrated the binding of polyamides to the U5 LTR in the conserved AT stretch. Third, changing the AT stretch into a GC stretch reduced the inhibitory activity of the bisdistamycins by 2 orders of magnitude.

The difference in anti-integration potency among the polyamides tested exceeded 2–3 orders of magnitude. This provided a basis for structure-activity relationships. Monomers were relatively inactive even at micromolar concentrations, thus suggesting a requirement of a dimeric form (bislexitropsins) for potent anti-IN activity. Among the bisdistamycins and novel lexitropsins, isomers with *para* substituted aromatic linkers consistently exhibited higher potency than *ortho* or *meta* substituted derivatives (Tables 1 and 2), implying the importance of a linear versus a folded arrangement for activity. Actually, the bisdistamycins with rigid linkers that tended to fold the molecule into a hairpin configuration (compounds **9**, **10**, **14**, and **15**) were not more potent inhibitors than distamycin (compound **7**). The greater activity of the linear bisdistamycins suggests that drug binding to an extended DNA segment is essential for inhibition of integration. Compounds with an aliphatic flexible linker composed of a hexamethylene or an octamethylene chain (compounds **17** and **18**) also were remarkably active, implying the importance of the size of the aliphatic chain linker for optimum potency. Finally, the finding that lexitropsins with substitutions on the distamycin moiety (compare compounds in Tables 1 and 2) remained active inhibitors of IN suggests that further chemical modifications can be made to improve antiviral activity.

In contrast to other IN inhibitors, such as catechol-containing compounds (Hazuda *et al.*, 1997a; Mazumder *et al.*, 1997), the lexitropsins were more active in  $Mg^{2+}$ -based assays than in the  $Mn^{2+}$ -based assays commonly used *in vitro*. Thus, if  $Mg^{+2}$  is more physiologically relevant than  $Mn^{+2}$ , it seems that polyamides are potential candidates to block integration *in vivo*.

Targeting of the conserved AT stretches of the LTRs (Bou-




**Fig. 10.** Importance of the conserved AT sequence for HIV-1 IN inhibition by bisdistamycins. A, The 21-mer blunt-end oligonucleotides where the AT stretch was replaced with GC (*underlined*). B, Concentration-dependent inhibition of HIV-1 IN by compounds **18** (□, ■) and **17** (○, ●) using native 21-mer oligonucleotide (○, ●) or the GC-modified oligonucleotide (■, ●).

ziane *et al.*, 1996) with lexitropsins (current study) represents a clear strategy for interfering with provirus integration and retrovirus replication. The remarkable conservation of the AT stretches in all the available HIV-1 LTRs (Fig. 1) suggests that synthetic polyamides might generally be active against a broad spectrum of HIV-1 viruses. It is noticeable that some of the synthetic polyamides tested exhibited significant antiviral activity (Table 1). Independent experiments demonstrated that such compounds inhibited reverse transcriptase only at high concentrations (150–200  $\mu M$  for compounds **1**, **2**, **5**, **6**, **10**, and **16**) (Lown JW, unpublished observations). Such concentrations are much higher than those required to inhibit integration. Further studies are warranted to determine whether integration is a prime mechanism for the antiviral activity of synthetic polyamides and to investigate whether other sites of the HIV genome and other viral processes are targeted by lexitropsins.

#### Acknowledgments

The assistance of the staff of the Drug Synthesis and Chemistry Branch, National Cancer Institute, is gratefully acknowledged. We also thank Drs. T. Jenkins and R. Craigie (Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD) for the mutant HIV-IN proteins and the expression system for wild-type HIV-IN.



**Fig. 11.** DNase I footprinting of the 21-mer oligonucleotide corresponding to the U5 end of the HIV-1 proviral DNA, 5' end-labeled with  $^{32}P$  in the presence of indicated concentrations of lexitropsins **17** and **18**.

## References

- Arts EJ and Wainberg MA (1996) Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. *Antimicrob Agents Chemother* **40**:527–540.
- Bouziane M, Cherny DI, Mouscadet JF, and Auclair C (1996) Alternate strand DNA triple helix-mediated inhibition of HIV-1 U5 long terminal repeat integration in vitro. *J Biol Chem* **271**:10359–10364.
- Bushman FD, Engelman A, Palmer I, Wingfield P, and Craigie R (1993) Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. *Proc Natl Acad Sci USA* **90**:3428–3432.
- Carteau S, Mouscadet JF, Goulaouic H, Subra F, and Auclair C (1993) Effect of topoisomerase inhibitors on the in vitro HIV DNA integration reaction. *Biochem Biophys Res Commun* **192**:1409–1414.
- Chow SA, Vincent KA, Ellison V, and Brown PO (1992) Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. *Science (Washington DC)* **255**:723–726.
- De Clercq E (1995) Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. *J Med Chem* **38**:2491–2517.
- De Clercq E (1996) Non-nucleoside reverse transcriptase inhibitors (NRTIs) for the treatment of immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. *Med Res Rev* **16**:125–157.
- Engelman A and Craigie R (1995) Efficient magnesium-dependent human immunodeficiency virus type 1 integrase activity. *J Virol* **69**:5908–5911.
- Engelman A, Mizuuchi K, and Craigie R (1991) HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. *Cell* **67**:1211–21.
- Erickson JW and Burt SK (1996) Structural mechanisms of HIV drug resistance. *Annu Rev Pharmacol Toxicol* **36**:545–571.
- Fesen MR, Kohn KW, Leteurtre F, and Pommier Y (1993) Inhibitors of human immunodeficiency virus integrase. *Proc Natl Acad Sci USA* **90**:2399–2403.
- Fesen MR, Pommier Y, Leteurtre F, Hiroguchi S, Yung J, and Kohn KW (1994) Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. *Biochem Pharmacol* **48**:595–608.
- Hazuda D, Felock P, Hastings J, Pramanik B, Wolfe A, Goodarzi G, Vora A, Brackmann K, and Grandgenett D (1997a) Equivalent inhibition of half-site and full-site retroviral strand transfer reactions by structurally diverse compounds. *J Virol* **71**:807–811.
- Hazuda DJ, Felock PJ, Hastings JC, Pramanik B, and Wolfe AL (1997b) Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase. *J Virol* **71**:7005–7011.
- Helene C (1998) Reading the minor groove. *Nature (Lond)* **391**:436–438.
- Johnson VA (1994) Combination therapy: more effective control of HIV type 1? *AIDS Res Hum Retrov* **10**:907–912.
- Katz RA and Skalka AM (1994) The retroviral enzymes. *Annu Rev Biochem* **63**:133–173.
- Kopka ML and Larsen TA (1992) *Netropsin and the Lexitropsins* (Propst CL and Perun TJ, eds) pp. 303–374, Marcel Dekker, New York.
- Kopka ML, Yoon C, Goodsell D, and Pjura P (1985) The molecular origin of DNA-drug specificity in netropsin and distamycin. *Proc Natl Acad Sci USA* **82**:1376–1380.
- Larder BA, Kemp SD, and Harrigan PR (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. *Science (Washington DC)* **269**:696–699.
- Lown JW (1988) Lexitropsins: rational design of DNA sequence reading agents as novel anti-cancer agents and potential cellular probes. *Anti-Cancer Drug Design* **3**:25–40.
- Lown JW (1994) DNA recognition by lexitropsins, minor groove binding agents. *J Mol Recognit* **7**:79–88.
- Lown JW, Krowicki KK, Balzarini J, Newman RA, and De Clercq E (1989) Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation. *J Med Chem* **32**:2368–2375.
- Mazumder A, Neamati N, Pilon AA, Sunder S, and Pommier Y (1996a) Chemical trapping of ternary complexes of human immunodeficiency virus type 1 integrase, divalent metal, and DNA substrates containing an abasic site: implications for the role of lysine 136 in DNA binding. *J Biol Chem* **271**:27330–27338.
- Mazumder A, Neamati N, Sunder S, Schulz J, Pertz H, Eich E, and Pommier Y (1997) Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. *J Med Chem* **40**:3057–3063.
- Mazumder A, Wang S, Neamati N, Nicklaus M, Sunder S, Chen J, Milne GW, Rice WG, Burke TR Jr, and Pommier Y (1996b) Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. *J Med Chem* **39**:2472–2481.
- Neamati N, Hong H, Mazumder A, Wang S, Sunder S, Nicklaus MC, Milne GWA, Proksa B, and Pommier Y (1997a) Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. *J Med Chem* **40**:942–951.
- Neamati N, Hong H, Sunder S, Milne GWA, and Pommier Y (1997b) Potent inhibitors of human immunodeficiency virus type 1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. *Mol Pharmacol* **52**:1041–1055.
- Neamati N, Sunder S, and Pommier Y (1997c) Design and discovery of HIV-1 integrase inhibitors. *Drug Discovery Today* **2**:487–498.
- Nishiwaki E, Tanaka S, Lee H, and Shibuya M (1988) Efficient synthesis of oligo-N-methyl pyrrolicarboxamides and related compounds. *Heterocycles* **27**:1945–1952.
- Pommier Y, Pilon AA, Bajaj K, Mazumder A, and Neamati N (1997) HIV-1 integrase as a target for antiviral drugs. *Antivir Chem Chemother* **8**:463–483.
- Rice P, Craigie R, and Davies DR (1996) Retroviral integrases and their cousins. *Curr Opin Struct Biol* **6**:76–83.
- Schinazi RF (1991) *Combined Chemotherapeutic Modalities for Viral Infections: Rationale and Clinical Potential* (Chou TC and Rideout DC, eds) pp. 109–181, Academic Press, Orlando, FL.
- Vink C, Yeheskiely E, van der Marel GA, van Boom JH, and Plasterk RH (1991) Site-specific hydrolysis and alcoholysis of human immunodeficiency virus DNA termini mediated by the viral integrase protein. *Nucleic Acids Res* **19**:6691–8.
- Wang W and Lown L (1992) Anti-HIV-1 activity of linked lexitropsins. *J Med Chem* **35**:2890–2897.
- Weislow OW, Kiser R, Fine D, Bader J, Shoemaker RH, and Boyd MR (1989) New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS antiviral activity. *J Natl Cancer Inst* **81**:577–586.
- White S, Szweczyk JW, Turner JM, Baird EE, and Dervan PB (1998) Recognition of the four Watson-Crick pairs in the DNA minor groove by synthetic ligands. *Nature (Lond)* **391**:468–470.
- Zimmer C, Luke G, Birch-Hiersfeld E, Weiss R, Arcamone F, and Guschlbauer W (1983) Chain length dependent association of distamycin-type oligopeptides with AT and GC pairs in polydeoxynucleotide duplexes. *Biochim Biophys Acta* **741**:15–22.
- Zimmer C, Puschendorf B, Grunkicke H, Chandra P, and Venner H (1977) Influence of netropsin and distamycin A on the secondary structure and template activity of DNA. *Eur J Biochem* **21**:269–278.

---

**Send reprint requests to:** Dr. Yves Pommier, Lab of Molecular Pharmacology, Division of Basic Sciences, NCI/NIH, Bldg. 37, Rm. 5D02, Bethesda, MD 20892-4255. E-mail: pommier@nih.gov

---